Trial Results Suggest Longer Mesothelioma Survival Possible with New...

Nintedanib boosted mesothelioma survival by more than five months in newly-published study.(PRWeb September 15, 2017)Read the full story at http://www.prweb.com/releases/2017/09/prweb14699696.htm
Source: PRWeb: Medical Pharmaceuticals - Category: Pharmaceuticals Source Type: news